0.3% Saline in 3.3% dextrose
DrugHypotonic Solutions: 0.3% Saline in 3.3% dextrose
Other names: Hypotonic Solutions: 0.3% Saline + 3.3% dextrose
NCT Number: NCT01909336
The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions.
Looking for future studies?
Notify Me3 month–15 year
All sexes
Interventional
Phase 3
Multicenter, Randomized, Controlled clinical trial.
The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions
This study will include 150 patients in 2 groups according to these type of pathology: group 1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and group 2: surgical conditions (pre, peri or postoperative patients will be included). Each group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution). In non-dehydrated patients the daily total volume of liquid infused will be determined by the volumetric Holliday- Segar* formula and the daily total volume will be calculated by adding the maintenance requirements (using the Holliday Segar formula) to the fluid deficit (according to percent of estimated weight**) in dehydrated patients.
The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%. The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24 hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the incidence of hyponatremia and the adverse clinical outcomes will be compared.
*0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; >20 kg: 1500 ml + 20ml/ kg over 20kg
** In patients under 10 kg correspond to a loss of 5% (50 mL/kg) in mild dehydration and 10% in moderate dehydration. In 10 kg or more: 3% (30 mL/kg) in mild dehydration and 6% (60 mL/kg) in moderate dehydration.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
Other names: Hypotonic Solutions: 0.3% Saline + 3.3% dextrose
Hypotonic Solutions: 0.45% Saline in 5% dextrose
Other names: Hypotonic Solutions: 0.45% Saline in 5% dextrose
Isotonic Solutions 0.9% Saline in 5% dextrose
Other names: Isotonic Solutions 0.9% Saline in 5% dextrose
Time frame: 8 hours
Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study
Time frame: 8 hours
hyponatraemia (defined as serum sodium < 135 mmol/L), normonatremia (defined as serum sodium 135-145 mmol/L) or hypernatraemia (defined as serum sodium > 145 mmol/L)
Time frame: 8 hours
Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 8 hours
Instituto Tecnologico y de Estudios Superiores de Monterey
Other
Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00201994
Brain Diseases, Cardiovascular Diseases
Gustav Carus, Dresden, Germany
View Trial DetailsNCT06781710
Demyelinating Diseases, Hyponatremia
Cologne, Germany
View Trial DetailsNCT01212211
Hyponatremia, Metabolic Diseases
Carentan, France
View Trial DetailsNCT07255833
Arrhythmias, Cardiac, Cardiovascular Diseases
Cologne, Germany
View Trial Details